Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, breakdown recent trial news from the 2 most popular incretin therapies: semaglutide and tirzepatide. First, hosts breakdown the November 24, 2025 announcement from Novo Nordisk disclosing their evoke and evoke+ trials of oral semaglutide in early symptomatic Alzheimer Disease failed to slow disease progression. Next, hosts break down the TIRTLE study, which examined use of tirzepatide in patients with type 1 diabetes.Semaglutide Misses Mark in Alzheimer DiseaseNovo Nordisk announced top-line results from the evoke and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.